March 27 (Reuters) - Bristol-Myers Squibb Co:
* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW
* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW
* BRISTOL-MYERS SQUIBB CO - FDA ALSO GRANTED OPDIVO PLUS YERVOY COMBINATION BREAKTHROUGH THERAPY DESIGNATION FOR THIS POTENTIAL INDICATION
* BRISTOL-MYERS SQUIBB CO - FDA ACTION DATE FOR FURTHER REGULATION ON THE SBLA IS JULY 10, 2018 Source text for Eikon: Further company coverage: